Evidence map›Paper›PMID 41476673›Full record

ArticleBreast cancer (Dove Medical Press)2025

Down-Regulation of lncRNA CKMT2-AS1 Predicts Poor Prognosis and Promotes Breast Cancer Progression.

Dengfeng Xue, Ruihong Hou, Huijuan Xu, Xinzheng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dengfeng Xue *Department of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Ruihong Hou *Department of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, People's Republic of China.
Huijuan XuDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Xinzheng LiDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This research aimed to ascertain the clinical implications of lncRNA CKMT2-AS1 and its underlying molecular mechanism in patients with breast cancer. Patients and Methods: CKMT2-AS1 expression were assessed in breast cancer. The prognostic implication of CKMT2-AS1 was evaluated using Cox regression analysis. Functional assays were conducted to explore the effects of CKMT2-AS1 on the cellular activities associated with breast cancer. Mechanistic investigations included dual-luciferase reporter assays, bioinformatics, and Western blot analyses to elucidate the molecular pathways involving CKMT2-AS1. Results: The analysis revealed that CKMT2-AS1 was significantly reduced in breast cancer tissue specimens and cell lines ( Conclusion: CKMT2-AS1 exerts its tumor-suppressing function in breast cancer via sequestering miR-106b-5p and modulating MECP2 expression. Its decreased levels are linked to the unfavorable prognosis, positioning CKMT2-AS1 as a prospective indicator for prognosticating breast cancer.

Indexed as

breast cancercell activityCKMT2-AS1MECP2miR-106b-5pprognosis

Identifiers

PMID41476673
PMCPMC12751299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.